Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1156 to 1170 of 1455 results for do not do recommendations

  1. Cabozantinib for treating medullary thyroid cancer (TA516)

    Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.

  2. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.

  3. Superior rectal artery embolisation for haemorrhoids (IPG627)

    Evidence-based recommendations on superior rectal artery embolisation for haemorrhoids in adults. This involves blocking the blood vessels supplying the haemorrhoids with tiny plastic particles or metal coils.

  4. Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (IPG598)

    Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults. This involves implanting a device under the skin in the chest and connecting it to a nerve under the tongue (hypoglossal nerve).

  5. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

  6. Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

    Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.

  7. 3C Patch for treating diabetic foot ulcers (MTG66)

    Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.

  8. Prontosan for treating acute and chronic wounds (MTG67)

    Evidence-based recommendations on Prontosan for treating acute and chronic wounds.

  9. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTE9)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders....

  10. PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)

    NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .

  11. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

  12. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

    Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.

  13. Proov Confirm for ovulation confirmation (MIB322)

    NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .

  14. Endoscopic injection of bulking agents for gastro-oesophageal reflux disease (IPG55)

    Evidence-based recommendations on endoscopic injection of bulking agents for gastro-oesophageal reflux disease. This involves injecting a filler into the junction using a catheter to make the entry to the stomach narrower, so that the contents of the stomach cannot pass back.

  15. Radiation therapy for early Dupuytren's disease (IPG573)

    Evidence-based recommendations on radiation therapy for early Dupuytren’s contractures in adults. This involves directing low energy X-rays at the affected tissue.